Covance, a global contract research organization, worked on all of the top 50 best-selling drugs available today through its full spectrum of nonclinical, clinical and commercialization services.
Covance is dedicated to advancing healthcare and delivering Solutions Made Real®
With precision delivery of the largest volume of drug development data on the planet, we can help you identify new approaches and anticipate tomorrow’s challenges. Learn more about our history and services.
ELISPOT Assay: A Powerful Tool in Vaccine Development
Learn about benefits and applicability across multiple immunology disciplines. Read the blog.
Immuno-oncology Education Center
Learn about the latest advances in Immuno-oncology. Download webinars, white papers, case studies and blogs.
New Approaches to Assessing Cardiac Drug Safety: Updates on ICH E14 and Moving Beyond Thorough QT Testing | July 25, 2017 - 11 a.m. ET
Take the Risk Out of Clinical Trials: How to Use Your Data to Minimize Risk and Issues
View the recording.
Assessing Abuse Potential: Regulatory Environment & Challenges. Watch the Webinar Recording Now.
Xcellerate® Informatics Suite
Successful clinical trials begin and end with the RIGHT data. Uncover new possibilities for your clinical trials with Xcellerate®, a fully integrated informatics platform. ONE comprehensive platform. UNPARALLELED RESULTS.
Connect With Us
Covance Xcellerate Informatics on LinkedIn
Keep up-to-date on the latest thinking from our experts and innovators.
Introducing biosimilar CMC analytical master files
Innovative & invaluable solutions for biosimilar development. Pre-developed, risk-mitigated biosimilarity assessment, testing solutions, data evaluation and consultation.
End-to-end drug & diagnostic development support for a new immuno-oncology agent
Find out how Covance/LabCorp helped a prominent pharmaceutical company enable a faster, more effective launch of their immuno-oncology drug.
Proactive risk management for ICH E6 compliance
Understand the recent changes to the ICH E6 guideline. Leverage a three-tier strategy.
Life Cycle Management
Maximize the value of your molecule through its life cycle.
Reaching the market isn’t the end of the road for your molecule. Covance Life Cycle Management (LCM) solutions ensure your molecule’s potential is fully realized.
Join us for an On Demand Webinar– Begin with the SEND in Mind: 2017 Challenges, Learnings and Opportunities
SEND are the Standards for the Exchange of Nonclinical Data. View our on demand webinar and obtain trusted insights regarding recent and upcoming changes to SEND regulatory requirements.
Immuno-oncology and the role of biomarkers, companion and complementary diagnostics
Learn more about how the use of a variety of biomarkers, companion diagnostics (CDx) and complementary diagnostics has powered the recent evolution of immunotherapies and their potential applications.
Analytical methods for bioanalysis
Check out our recently updated nonproprietary assay list featuring more than 330 compounds.
Biomarkers and immuno-oncology: Identifying new opportunities for precision medicine | Watch the recording now
Have you visited the NASH Education Center?
We’re pleased to announce the launch of the NASH Education Center. Access the latest thoughts from experts through webinars, case studies, blogs, info sheets and scientific articles.
Phase IIb/III Clinical Trials
Your approval. Our common goal.
As you move over to high stakes clinical development, you’ll benefit from an end-to-end suite of services, relentlessly focused on your drug’s approval.
Multiple indications. A fundamental approach.
Experience with 14 of the 15 top IMID drugs. Over 470 IMID clinical trials in the past five years. A broad, well-coordinated platform of services
Exceptional people. Extraordinary paths.
Discover your potential with a company that truly invests in you.
The diabetic heart: A focus on heart failure recording now available
Hear an insightful discussion on how certain molecular classes impact CV outcomes for patients with type 2 diabetes along with strategies for testing new therapeutic, paradigm-modifying treatment modalities.